EPAS1 and hereditary pheochromocytoma-paraganglioma: Belzutifan is a promising HIF-2α inhibitor being studied in clinical trials for pheochromocytomas and is currently the only HIF-2α inhibitor therapy approved in the United States for the treatment of patients with VHL-related tumors [91,92].